Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Nicotine vaccine NIC-002 enters phase II study

Nov. 8, 2010

AEOL-10150 promotes survival in nonhuman primates exposed to radiation

Nov. 5, 2010

Soligenix presents preliminary phase Ib safety data on RiVax

Nov. 4, 2010

Alkermes' combination therapy for cocaine addiction to advance to phase II

Oct. 26, 2010

Omeros receives additional grant from NIDA for addiction program

Oct. 18, 2010

FDA approves Vivitrol for prevention of relapse to opioid dependence

Oct. 13, 2010

Embera NeuroTherapeutics obtains NIDA grant for EMB-001 development

Oct. 5, 2010

Cleveland BioLabs reports on second safety study of CBLB-502

Oct. 1, 2010

FDA approves phase Ib ibudilast trial in methamphetamine-dependent subjects

Sep. 29, 2010

FDA committee recommends approval of Vivitrol for opioid dependence

Sep. 20, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...